(S (NP (NN Sepsis)) (VP (VBZ is) (NP (NP (DT a) (JJ life-threatening) (NN condition)) (VP (VBG affecting) (NP (QP (CD one) (CD million)) (NNS people)) (PP (IN per) (NP (NN year))) (PP (IN in) (NP (DT the) (NNP US)))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NN dysregulation)) (PP (IN of) (NP (NP (DT the) (NN body) (POS 's)) (JJ own) (NN immune) (NN system)))) (VP (VBZ causes) (NP (NP (NN damage)) (PP (TO to) (NP (PRP$ its) (NNS tissues)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (DT a) (ADJP (QP (CD 28) (: -) (CD 50)) (NN %)) (NN mortality) (NN rate)))))))))) (. .))
(S (NP (NP (JJ Clinical) (NNS trials)) (PP (IN for) (NP (NN sepsis) (NN treatment))) (PP (IN over) (NP (DT the) (JJ last) (CD 20) (NNS years)))) (VP (VBP have) (VP (VBN failed) (S (VP (TO to) (VP (VB produce) (NP (DT a) (JJ single) (ADJP (RB currently) (NNP FDA) (VBD approved)) (NN drug) (NN treatment))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP attempt) (S (VP (TO to) (VP (VB discover) (NP (NP (DT an) (JJ effective) (NN cytokine) (NN mediation) (NN treatment) (NN strategy)) (PP (IN for) (NP (NN sepsis)))) (S (VP (VBG using) (NP (NP (DT a) (ADJP (RB previously) (VBN developed)) (JJ agent-based) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (VBZ simulates) (NP (NP (DT the) (NN innate) (JJ immune) (NN response)) (PP (TO to) (NP (NN infection))))))) (: :) (NP (NP (DT the) (NNP Innate) (NNP Immune) (NNP Response) (JJ agent-based) (NN model)) (PRN (-LRB- -LRB-) (NP (NNP IIRABM)) (-RRB- -RRB-)))))))))) (. .))
(S (NP (NP (JJ Previous) (NNS attempts)) (PP (IN at) (S (VP (VBG reducing) (NP (NN mortality)) (PP (IN with) (NP (JJ multi-cytokine) (NN mediation))) (S (VP (VBG using) (NP (DT the) (NNP IIRABM)))))))) (VP (VP (VBP have) (VP (VBN failed) (S (VP (TO to) (VP (VB reduce) (NP (NN mortality)) (PP (IN across) (NP (DT all) (NN patient) (NNS parameterizations)))))))) (CC and) (VP (VBD motivated) (S (NP (PRP us)) (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (JJ adaptive) (, ,) (JJ personalized) (JJ multi-cytokine) (NN mediation)) (VP (MD can) (VP (VP (VB control) (NP (NP (DT the) (NN trajectory)) (PP (IN of) (NP (NN sepsis))))) (CC and) (VP (JJR lower) (NP (NN patient) (NN mortality)))))))))))) (. .))
(S (NP (PRP We)) (VP (VBD used) (NP (DT the) (NNP IIRABM)) (S (VP (TO to) (VP (VB compute) (NP (NP (DT a) (NN treatment) (NN policy)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ systemic) (NN patient) (NNS measurements)) (VP (VBP are) (VP (VBN used) (PP (IN in) (NP (DT a) (NN feedback) (NN loop))) (S (VP (TO to) (VP (VB inform) (NP (JJ future) (NN treatment)))))))))))))) (. .))
(S (S (VP (VBG Using) (NP (JJ deep) (NN reinforcement) (NN learning)))) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (NP (DT a) (NN policy)) (SBAR (WHNP (WDT that)) (S (VP (VBZ achieves) (NP (ADJP (CD 0) (NN %)) (NN mortality)) (PP (IN on) (NP (NP (DT the) (JJ patient) (NN parameterization)) (SBAR (WHPP (IN on) (WHNP (WDT which))) (S (NP (PRP it)) (VP (VBD was) (VP (VBN trained)))))))))))) (. .))
(S (ADVP (RBR More) (RB importantly)) (, ,) (NP (DT this) (NN policy)) (ADVP (RB also)) (VP (VBZ achieves) (NP (ADJP (CD 0.8) (NN %)) (NN mortality)) (PP (IN over) (NP (NP (CD 500) (ADJP (RB randomly) (VBN selected)) (JJ patient) (NNS parameterizations)) (PP (IN with) (NP (NP (NP (NN baseline) (NNS mortalities)) (VP (VBG ranging) (PP (IN from) (CD 1) (: -) (NP (CD 99) (NN %)))) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (CD 49) (NN %))))) (-RRB- -RRB-))) (VP (VBG spanning) (NP (NP (DT the) (JJ entire) (ADJP (RB clinically) (JJ plausible)) (NN parameter) (NN space)) (PP (IN of) (NP (DT the) (NNP IIRABM)))))))))) (. .))
(S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ adaptive) (, ,) (JJ personalized) (JJ multi-cytokine) (NN mediation) (NN therapy)) (VP (MD could) (VP (VB be) (NP (NP (DT a) (JJ promising) (NN approach)) (PP (IN for) (S (VP (VBG treating) (NP (NN sepsis))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP hope) (SBAR (IN that) (S (NP (DT this) (NN work)) (VP (VBZ motivates) (S (NP (NNS researchers)) (VP (TO to) (VP (VB consider) (NP (PDT such) (DT an) (NN approach)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (JJ future) (JJ clinical) (NNS trials)))))))))))) (. .))
(S (PP (TO To) (NP (NP (DT the) (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (, ,) (NP (DT this) (NN work)) (VP (VP (VBZ is) (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VB consider) (NP (NP (JJ adaptive) (, ,) (JJ personalized) (JJ multi-cytokine) (NN mediation) (NN therapy)) (PP (IN for) (NP (NN sepsis)))))))))) (, ,) (CC and) (VP (VBZ is) (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VB exploit) (NP (JJ deep) (NN reinforcement) (VBG learning)) (PP (IN on) (NP (DT a) (JJ biological) (NN simulation)))))))))) (. .))
